Literature DB >> 19288063

A vitronectin M381T polymorphism increases risk of hemangioblastoma in patients with VHL gene defect.

Jing-Shan Huang1, Chih-Ming Lin, Yu-Che Cheng, Kun-Long Hung, Chih-Cheng Chien, Shao-Kuan Chen, Chih-Ju Chang, Chan-Wei Chen, Chi-Jung Huang.   

Abstract

Hemangioblastomas, highly vascular tumors, occur sporadically or associated with von Hippel-Lindau (VHL) disease. Diverse mutations in the VHL gene inactivate the VHL protein and constitute the molecular etiology of the disease. Changes in VHL gene were analyzed in patients with multiplex ligation-dependent probe amplification and single-strand conformation polymorphism analyses. We report here that other angiogenesis-related changes in vitronectin were identified with 2D electrophoresis of plasma samples and restriction fragment length polymorphisms. Our findings revealed that most patients (80.0%) with a familial VHL deletion carried the threonine (T) allele at vitronectin codon 381. Adults simultaneously carrying a VHL defect and the T allele were 5.0-fold more likely to be affected by VHL disease than were methionine/methionine (M/M) homozygotes carrying a VHL defect. Patients with sporadic hemangioblastoma, C-terminally truncated VHL protein or a large deletion in the VHL gene, and the T allele were 18.0-fold more likely to develop recurrent disease. Taken together, individuals with mutated VHL are more likely to be affected by familial or recurrent sporadic hemangioblastoma when carrying the M/T or T/T genotype at codon 381 of vitronectin.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19288063     DOI: 10.1007/s00109-009-0456-1

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  52 in total

Review 1.  Proteomics: a new approach to the study of disease.

Authors:  G Chambers; L Lawrie; P Cash; G I Murray
Journal:  J Pathol       Date:  2000-11       Impact factor: 7.996

2.  Detection of germline deletions using real-time quantitative polymerase chain reaction in Japanese patients with von Hippel-Lindau disease.

Authors:  Keiko Hattori; Jun-ichi Teranishi; Catherine Stolle; Minoru Yoshida; Kei-ichi Kondo; Takeshi Kishida; Hiroshi Kanno; Masaya Baba; Yoshinobu Kubota; Masahiro Yao
Journal:  Cancer Sci       Date:  2006-05       Impact factor: 6.716

3.  Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein.

Authors:  M E Cockman; N Masson; D R Mole; P Jaakkola; G W Chang; S C Clifford; E R Maher; C W Pugh; P J Ratcliffe; P H Maxwell
Journal:  J Biol Chem       Date:  2000-08-18       Impact factor: 5.157

4.  Proteomic identification of a role for the von Hippel Lindau tumour suppressor in changes in the expression of mitochondrial proteins and septin 2 in renal cell carcinoma.

Authors:  Rachel A Craven; Sarah Hanrahan; Nick Totty; Patricia Harnden; Anthea J Stanley; Eamonn R Maher; Adrian L Harris; William S Trimble; Peter J Selby; Rosamonde E Banks
Journal:  Proteomics       Date:  2006-07       Impact factor: 3.984

5.  Characterization of human S protein, an inhibitor of the membrane attack complex of complement. Demonstration of a free reactive thiol group.

Authors:  B Dahlbäck; E R Podack
Journal:  Biochemistry       Date:  1985-04-23       Impact factor: 3.162

6.  Characteristic chromosomal aberrations in sporadic cerebellar hemangioblastomas revealed by comparative genomic hybridization.

Authors:  S H Sprenger; J M Gijtenbeek; P Wesseling; R Sciot; F van Calenbergh; M Lammens; J W Jeuken
Journal:  J Neurooncol       Date:  2001-05       Impact factor: 4.130

7.  The -148 C/T fibrinogen gene polymorphism and fibrinogen levels in ischaemic stroke: a case-control study.

Authors:  M P J van Goor; E B Gómez-García; F W G Leebeek; G J Brouwers; P J Koudstaal; D W J Dippel
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-01       Impact factor: 10.154

8.  Software and database for the analysis of mutations in the VHL gene.

Authors:  C Béroud; D Joly; C Gallou; F Staroz; M T Orfanelli; C Junien
Journal:  Nucleic Acids Res       Date:  1998-01-01       Impact factor: 16.971

9.  The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin.

Authors:  Hilary A Kenny; Swayamjot Kaur; Lisa M Coussens; Ernst Lengyel
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

10.  Heparin-binding vitronectin up-regulates latent TGF-beta production by bovine aortic endothelial cells.

Authors:  S M Ribeiro; S Schultz-Cherry; J E Murphy-Ullrich
Journal:  J Cell Sci       Date:  1995-04       Impact factor: 5.285

View more
  4 in total

1.  Beyond the Knudson's hypothesis in von Hippel-Lindau (VHL) disease-proposing vitronectin as a "gene modifier".

Authors:  Francesco Turturro
Journal:  J Mol Med (Berl)       Date:  2009-06       Impact factor: 4.599

2.  Vitronectin and Its Interaction with PAI-1 Suggests a Functional Link to Vascular Changes in AMD Pathobiology.

Authors:  Fabiola Biasella; Tobias Strunz; Christina Kiel; Bernhard H F Weber; Ulrike Friedrich
Journal:  Cells       Date:  2022-05-27       Impact factor: 7.666

3.  Structure of human Vitronectin C-terminal domain and interaction with Yersinia pestis outer membrane protein Ail.

Authors:  Kyungsoo Shin; Bernhard C Lechtenberg; Lynn M Fujimoto; Yong Yao; Sara Schesser Bartra; Gregory V Plano; Francesca M Marassi
Journal:  Sci Adv       Date:  2019-09-11       Impact factor: 14.136

4.  Knocking down of heat-shock protein 27 directs differentiation of functional glutamatergic neurons from placenta-derived multipotent cells.

Authors:  Yu-Che Cheng; Chi-Jung Huang; Yih-Jing Lee; Lu-Tai Tien; Wei-Chi Ku; Raymond Chien; Fa-Kung Lee; Chih-Cheng Chien
Journal:  Sci Rep       Date:  2016-07-22       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.